Department of Epidemiology, Columbia University, New York, NY, USA.
Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA.
J R Soc Interface. 2022 Jun;19(191):20210900. doi: 10.1098/rsif.2021.0900. Epub 2022 Jun 6.
The Delta variant is a major SARS-CoV-2 variant of concern first identified in India. To better understand COVID-19 pandemic dynamics and Delta, we use multiple datasets and model-inference to reconstruct COVID-19 pandemic dynamics in India during March 2020-June 2021. We further use the large discrepancy in one- and two-dose vaccination coverage in India (53% versus 23% by end of October 2021) to examine the impact of vaccination and whether prior non-Delta infection can boost vaccine effectiveness (VE). We estimate that Delta escaped immunity in 34.6% (95% CI: 0-64.2%) of individuals with prior wild-type infection and was 57.0% (95% CI: 37.9-75.6%) more infectious than wild-type SARS-CoV-2. Models assuming higher VE among non-Delta infection recoverees, particularly after the first dose, generated more accurate predictions than those assuming no such increases (best-performing VE setting: 90/95% versus 30/67% baseline for the first/second dose). Counterfactual modelling indicates that high vaccination coverage for first vaccine dose in India combined with the boosting of VE among recoverees averted around 60% of infections during July-mid-October 2021. These findings provide support to prioritizing first-dose vaccination in regions with high underlying infection rates, given continued vaccine shortages and new variant emergence.
德尔塔变异株是一种令人关注的主要 SARS-CoV-2 变异株,最初在印度被发现。为了更好地了解 COVID-19 大流行的动态和德尔塔变异株,我们使用多个数据集和模型推断,重建了 2020 年 3 月至 2021 年 6 月期间印度的 COVID-19 大流行动态。我们进一步利用印度一剂和两剂疫苗接种覆盖率之间的巨大差异(截至 2021 年 10 月底,分别为 53%和 23%),来检验疫苗接种的影响,以及先前非德尔塔感染是否能提高疫苗有效性(VE)。我们估计,德尔塔变异株在 34.6%(95%CI:0-64.2%)有先前野生型感染的个体中逃避了免疫,比野生型 SARS-CoV-2 更具传染性,感染力高出 57.0%(95%CI:37.9-75.6%)。假设非德尔塔感染康复者,特别是在接种第一剂疫苗后,具有更高 VE 的模型比假设没有此类增加的模型产生更准确的预测(表现最佳的 VE 设置:第一/第二剂分别为 90/95%对 30/67%基线)。反事实模型表明,印度高比例的一剂疫苗接种覆盖率加上康复者 VE 的提高,在 2021 年 7 月至 10 月中旬期间避免了约 60%的感染。鉴于疫苗持续短缺和新变异株的出现,这些发现为在高基础感染率地区优先接种第一剂疫苗提供了支持。